The efficacy and safety of CAR-T cell therapy in patients with refractory ALL and concomitant HBV infection

被引：5

作者：

Lai, Peilong ^{[1
,2
,3
]}

Chen, Xiaomei ^{[1
]}

Qin, Le ^{[2
]}

Jiang, Zhiwu ^{[2
]}

Luo, Chenwei ^{[1
]}

Huang, Xin ^{[1
]}

Wu, Sujing ^{[1
]}

Ling, Wei ^{[1
]}

Wang, Yulian ^{[1
]}

Wang, Jinghua ^{[1
]}

Deng, Chenxin ^{[1
]}

Huang, Lisi ^{[1
]}

Zeng, Lingji ^{[1
]}

Lu, Zesheng ^{[1
]}

Zhong, Liye ^{[1
]}

Liao, Pengjun ^{[1
]}

Li, Minming ^{[1
]}

Chen, Dongmei ^{[2
]}

Geng, Suxia ^{[1
]}

Wu, Ping ^{[1
]}

Tang, Zhaoyang ^{[4
]}

Pei, Duanqing ^{[2
,3
]}

Du, Xin ^{[1
]}

Li, Peng ^{[2
,3
]}

Weng, Jianyu ^{[1
]}

机构：

[1] Guangdong Prov Peoples Hosp, Guangdong Acad Med Sci, Dept Hematol, Guangzhou 510080, Guangdong, Peoples R China

[2] Chinese Acad Sci, Guangzhou Inst Biomed & Hlth, Univ Chinese Acad Sci, State Key Lab Resp Dis, Guangzhou 510530, Guangdong, Peoples R China

[3] Chinese Acad Sci, Guangdong Prov Key Lab Stem Cell & Regenerat Med, South China Inst Stem Cell Biol & Regenerat Med, Guangzhou Inst Biomed & Hlth,Univ Chinese Acad Sc, Guangzhou 510530, Guangdong, Peoples R China

[4] Guangdong Zhaotai InVivo Biomed Co Ltd, Guangzhou 510000, Peoples R China

来源：

LEUKEMIA | 2020年 / 34卷 / 10期

基金：

中国国家自然科学基金;

关键词：

D O I：

10.1038/s41375-020-0952-4

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

[No abstract available]

引用

页码：2790 / 2793

页数：4

共 50 条

[41] Safety and efficacy of B7-H3 targeting CAR-T cell therapy for patients with recurrent GBM
Zhang, Yang
Feng, Rui
Chi, Xiaohan
Xian, Na
Chen, Xianzhen
Huang, Na
Zhang, Yu
Zhang, Kangna
Zhang, Jindong
Chen, Lieping
Ji, Nan
Huang, Gangxiong
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[42] FIRST EVIDENCE FOR EFFICACY OF CAR-T CELL TREATMENT IN REFRACTORY ANTISYNTHETASE SYNDROME
Taubmann, J.
Mueller, F.
Boeltz, S.
Knitza, J.
Voelkl, S.
Aigner, M.
Kleyer, A.
Minnopoulou, I.
Locatelli, F.
D'agostino, M. A.
Gary, R.
Krestchmann, S.
Kharboutli, S.
Mougiakakos, D.
Kroenke, G.
Andreas, M.
Schett, G.
ANNALS OF THE RHEUMATIC DISEASES, 2023, 82 : 957 - 958
[43] CAR-T CELL THERAPY FOR CHILDREN, ADOLESCENTS, AND YOUNG ADULTS WITH ALL
Kato, Itaru
PEDIATRIC BLOOD & CANCER, 2024, 71 : S6 - S6
[44] B cell lineage reconstitution underlies CAR-T cell therapeutic efficacy in patients with refractory myasthenia gravis
Tian, Dai-Shi
Qin, Chuan
Dong, Ming-Hao
Heming, Michael
Zhou, Luo-Qi
Wang, Wen
Cai, Song-Bai
You, Yun-Fan
Shang, Ke
Xiao, Jun
Wang, Di
Li, Chun-Rui
Zhang, Min
Bu, Bi-Tao
Meyer zu Hoerste, Gerd
Wang, Wei
EMBO MOLECULAR MEDICINE, 2024, 16 (04) : 966 - 987
[45] Subsequent Secondary CAR-T Cell Therapy Was Superior to Chemotherapy in Patients with Refractory/Relapsed BCell Lymphoma after Failure of Anti-CD19 CAR-T Cell Therapy
Yang, Fan
Liu, Rui
Xu, Teng
Zheng, Peihao
Feng, Shaomei
Guo, Yuelu
Ma, Lixia
Shi, Hui
Deng, Biping
Ke, Xiaoyan
Wu, Tong
Hu, Kai
BLOOD, 2022, 140 : 10384 - 10385
[46] Efficacy of anti-CD19 CAR-T cell therapy in 10 refractory recurrent B cell malignancies
包芳
China Medical Abstracts (Internal Medicine), 2018, 35 (03) : 186 - 187
[47] Biomarkers for CAR-T Cell Therapy
不详
TRANSFUSIONSMEDIZIN, 2024, 14 (03) : 123 - 124
[48] CAR-T CELL TREATMENT OF REFRACTORY SYSTEMIC LUPUS ERYTHEMATOSUS- SAFETY AND PRELIMINARY EFFICACY DATA FROM THE FIRST FOUR PATIENTS
Schett, G.
Boeltz, S.
Mueller, F.
Kleyer, A.
Voelkl, S.
Aigner, M.
Gary, R.
Kretschmann, S.
Simon, D.
Kharboutli, S.
Mougiakakos, D.
Kroenke, G.
Andreas, M.
ANNALS OF THE RHEUMATIC DISEASES, 2022, 81 : 185 - 185
[49] CAR-T Cell Therapy and Beyond
Dotti, Gianpietro
PEDIATRIC BLOOD & CANCER, 2017, 64 : S4 - S4
[50] LONG TERM SAFETY AND EFFICACY OF CAR-T CELL TREATMENT IN REFRACTORY SYSTEMIC LUPUS ERYTHEMATOSUS - DATA FROM THE FIRST SEVEN PATIENTS
Taubmann, J.
Mueller, F.
Boeltz, S.
Voelkl, S.
Aigner, M.
Kleyer, A.
Minnopoulou, I.
Locatelli, F.
D'agostino, M. A.
Gary, R.
Krestchmann, S.
Kharboutli, S.
Mougiakakos, D.
Kroenke, G.
Andreas, M.
Schett, G.
ANNALS OF THE RHEUMATIC DISEASES, 2023, 82 : 93 - 94

← 1 2 3 4 5 →